InsidersTradesSigma
Total declarations
Companies
▲ Purchases (18 ops.)
▼ Sales (3 ops.)
Insider track record
Board DirectorDisclosed buys
18
Disclosed sells
3
T+90 hit rate
75%
T+90 mean return
+0.8%
Across 4 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Explore the complete record of transactions filed by Gordon Carl l, Director. Insider active across 11 companies, notably Theseus Pharmaceuticals, Inc.. Aggregated, 36 disclosures have been published. Split: 18 buys · 3 sells. Total volume traded: €58m. History available since 4 November 2021. The latest transaction was disclosed on 10 August 2026 (Acquisition). Regulator: SEC (Form 4). All data is free.
Companies and markets linked to Gordon Carl l
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations36 total
625,000 shares@ US$16.00100.0% of flowCommon StockSEC:0000947871-26-000785:2
Canonical exit: 8 Nov 2026 (T+90)
1,039,996 sharesCommon StockSEC:0000947871-26-000785:0
1,049,283 sharesCommon StockSEC:0000947871-26-000785:1
1,000,000 shares@ US$15.00100.0% of flowCommon StockSEC:0000947871-26-000734:1
Canonical exit: 25 Oct 2026 (T+90)
348,825 sharesCommon StockSEC:0000947871-26-000734:0
140,057 shares@ US$17.7519.6% of flowCommon StockSEC:0000947871-25-001084:0
5,250 shares0Common StockSEC:0001415889-25-015978:0
3,571,428 shares@ US$1.5929.9% of flowCommon StockSEC:0000947871-25-000385:0
17,962 shares@ US$9.90100.0% of flowCommon StockSEC:0000947871-25-000200:0
Canonical exit: 15 May 2025 (T+90)
323,916 shares@ US$3.20100.0% of flowCommon StockSEC:0001213900-24-094665:0
2,658,428 sharesCommon StockSEC:0000950170-24-107524:0
220,600 shares@ US$44.01100.0% of flowCommon StockSEC:0000947871-24-000703:0
39,433 shares@ US$10.005.0% of flowCommon StockSEC:0000947871-24-000628:0
5,900 shares0Common StockSEC:0000950170-24-070616:0
1,368,339 sharesCommon StockSEC:0000947871-24-000354:0
17,063,000 sharesCommon StockSEC:0001104659-24-023559:0
821,827 sharesCommon StockSEC:0001104659-24-008797:0
1,841,100 shares@ US$2.4042.2% of flowCommon StockSEC:0000950170-24-008052:0
Canonical exit: 24 Apr 2024 (T+90)
328,482 shares@ US$3.0541.9% of flowCommon StockSEC:0000947871-23-000761:0
Canonical exit: 15 Oct 2023 (T+90)
125,000 shares@ US$2.092.5% of flowCommon StockSEC:0000947871-23-000714:0
Canonical exit: 25 Sept 2023 (T+90)
5,900 shares0Common StockSEC:0001209191-23-033957:0
83,459 shares@ US$2.7511.9% of flowCommon StockSEC:0000947871-23-000540:0
Canonical exit: 2 Aug 2023 (T+90)
60,998 shares@ US$2.558.1% of flowCommon StockSEC:0000947871-23-000516:0
Canonical exit: 27 Jul 2023 (T+90)
550,000 sharesCommon StockSEC:0000947871-23-000215:0
137,931 shares@ US$7.2513.1% of flowCommon StockSEC:0000947871-22-001259:0
Canonical exit: 23 Mar 2023 (T+90)
25 of 36 declarations
About Gordon Carl l
GORDON CARL L is Administrateur and has filed 31 disclosures. In the sampled recent filings, buys total 21844360 EUR and sells total 16530348 EUR, over the period from 2021-10-14 to 2025-12-18. He appears as a director of Theseus Pharmaceuticals, Inc., Compass Therapeutics, Inc., Adicet Bio, Inc., Kinnate Biopharma Inc., Keros Therapeutics, Inc. and Terns Pharmaceuticals, Inc.
